ALB and Cirrhosis: One-fourth of the cohort of 642 patients with advanced/decompensated HCV-related cirrhosis achieved a significant improvement in liver function parameters in the short-term follow-up, whereas over a median observation of 4 years after DAA therapy, the mean changes in bilirubin, albumin, and MELD values were marginal.